Consumers and health professionals are advised that the sponsor of tranylcypromine 10 mg tablets (marketed under the brand name Parnate) has extended the period of expected shortage until 31 January 2021 due to unforeseen delays.
The Therapeutic Goods Administration (TGA) previously published information about this shortage in its medicine shortages database (search for either 'tranylcypromine' or 'Parnate') and in a safety alert.
The TGA is working closely with the sponsor of this medicine, Amdipharm Mercury (Australia) Pty Ltd, to minimise the impact of the shortage on patients. In particular, the TGA has authorised Amdipharm to supply an overseas-registered brand of tranylcypromine under Section 19A of the Therapeutic Goods Act 1989 to help meet demand.
Amdipharm continues to reserve an emergency supply of tranylcypromine for patients whose pharmacies cannot get stock from their usual suppliers. Pharmacists can contact Amdipharm on 02 9431 6333 or 1800 627 680 to enquire about the emergency supply.
The TGA has also authorised supply of additional Section 19A products. Further information about alternative tranylcypromine products is available in our Section 19A database (search for 'tranylcypromine' or 'Parnate').
Enquires about supply of these products should be directed to the Section 19A approval holders.
Reporting problems
Consumers and health professionals are encouraged to report problems with medicines or vaccines. Your report will contribute to the TGA's monitoring of these products.
The TGA cannot give advice about an individual's medical condition. You are strongly encouraged to talk with a health professional if you are concerned about a possible adverse event associated with a medicine or vaccine.